Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.
Identifieur interne : 004483 ( Main/Exploration ); précédent : 004482; suivant : 004484Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.
Auteurs : RBID : pubmed:8824563English descriptors
- KwdEn :
- Antibodies, Bispecific (pharmacokinetics), Antibodies, Bispecific (therapeutic use), Carcinoembryonic Antigen (immunology), Carcinoembryonic Antigen (metabolism), Colonic Neoplasms (immunology), Colonic Neoplasms (metabolism), Colonic Neoplasms (radiotherapy), Half-Life, Humans, Immunoglobulin Fab Fragments (metabolism), Indium Radioisotopes (pharmacokinetics), Iodine Radioisotopes (pharmacokinetics), Microscopy, Electron, Scanning, Radioimmunotherapy (methods), Spheroids, Cellular (immunology), Spheroids, Cellular (metabolism), Temperature, Time Factors, Tumor Cells, Cultured.
- MESH :
- chemical , immunology : Carcinoembryonic Antigen.
- chemical , metabolism : Carcinoembryonic Antigen, Immunoglobulin Fab Fragments.
- chemical , pharmacokinetics : Antibodies, Bispecific, Indium Radioisotopes, Iodine Radioisotopes.
- chemical , therapeutic use : Antibodies, Bispecific.
- immunology : Colonic Neoplasms, Spheroids, Cellular.
- metabolism : Colonic Neoplasms, Spheroids, Cellular.
- methods : Radioimmunotherapy.
- radiotherapy : Colonic Neoplasms.
- Half-Life, Humans, Microscopy, Electron, Scanning, Temperature, Time Factors, Tumor Cells, Cultured.
Abstract
In the perspective of radioimmunotherapy (RIT) of micrometastases, we compared, in multicell spheroids (MS), the uptake and retention kinetics of 125I-F(ab)'2 F6 anti-carcinoembryonic antigen (CEA) monoclonal antibody (MAb), and the affinity enhancement system (AES) using an anti-CEA/anti-DTPA-indium bispecific antibody (BsMAb) and a 125I-labeled di-DTPA-In-tyrosine-lysine bivalent hapten. We used MS of colorectal tumor cell lines expressing CEA strongly (LS 174T), weakly (HT-29) or not at all (HRT-18). Uptake and retention kinetics of 125I-F(ab)'2 F6 and 125I-BsMAb used alone gave similar results. The highest uptake values, obtained with LS 174T MS, were slightly lower with AES than with 125I-F(ab)'2 F6. However, effective retention half-lives were longer for AES than for 125I-F(ab)'2 F6 or for 111In-labeled monovalent hapten after pre-incubation of spheroids with BsMAb. Autoradiography showed the same slow and heterogeneous distribution of 125I-F(ab)'2 F6 and 125I-BsMAb. These results indicate that the 2-step technique is more favorable for RIT: uptake values were approximately the same but uptake kinetics were more rapid, and retention half-life was longer than with the one-step technique.
DOI: 10.1002/(SICI)1097-0215(19960917)67:6<883::AID-IJC20>3.0.CO;2-1
PubMed: 8824563
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.</title><author><name sortKey="Devys, A" uniqKey="Devys A">A Devys</name><affiliation wicri:level="1"><nlm:affiliation>Unité 211 INSERM, Institut de Biologie, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité 211 INSERM, Institut de Biologie, Nantes</wicri:regionArea><placeName><region type="région">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Thedrez, P" uniqKey="Thedrez P">P Thedrez</name></author><author><name sortKey="Gautherot, E" uniqKey="Gautherot E">E Gautherot</name></author><author><name sortKey="Faivre Chauvet, A" uniqKey="Faivre Chauvet A">A Faivre-Chauvet</name></author><author><name sortKey="Sai Maurel, C" uniqKey="Sai Maurel C">C Saï-Maurel</name></author><author><name sortKey="Rouvier, E" uniqKey="Rouvier E">E Rouvier</name></author><author><name sortKey="Auget, J L" uniqKey="Auget J">J L Auget</name></author><author><name sortKey="Barbet, J" uniqKey="Barbet J">J Barbet</name></author><author><name sortKey="Chatal, J F" uniqKey="Chatal J">J F Chatal</name></author></titleStmt><publicationStmt><date when="1996">1996</date><idno type="RBID">pubmed:8824563</idno><idno type="pmid">8824563</idno><idno type="doi">10.1002/(SICI)1097-0215(19960917)67:6<883::AID-IJC20>3.0.CO;2-1</idno><idno type="wicri:Area/Main/Corpus">004533</idno><idno type="wicri:Area/Main/Curation">004533</idno><idno type="wicri:Area/Main/Exploration">004483</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Bispecific (pharmacokinetics)</term><term>Antibodies, Bispecific (therapeutic use)</term><term>Carcinoembryonic Antigen (immunology)</term><term>Carcinoembryonic Antigen (metabolism)</term><term>Colonic Neoplasms (immunology)</term><term>Colonic Neoplasms (metabolism)</term><term>Colonic Neoplasms (radiotherapy)</term><term>Half-Life</term><term>Humans</term><term>Immunoglobulin Fab Fragments (metabolism)</term><term>Indium Radioisotopes (pharmacokinetics)</term><term>Iodine Radioisotopes (pharmacokinetics)</term><term>Microscopy, Electron, Scanning</term><term>Radioimmunotherapy (methods)</term><term>Spheroids, Cellular (immunology)</term><term>Spheroids, Cellular (metabolism)</term><term>Temperature</term><term>Time Factors</term><term>Tumor Cells, Cultured</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Carcinoembryonic Antigen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Carcinoembryonic Antigen</term><term>Immunoglobulin Fab Fragments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Bispecific</term><term>Indium Radioisotopes</term><term>Iodine Radioisotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Bispecific</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Colonic Neoplasms</term><term>Spheroids, Cellular</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Colonic Neoplasms</term><term>Spheroids, Cellular</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radioimmunotherapy</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Colonic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Half-Life</term><term>Humans</term><term>Microscopy, Electron, Scanning</term><term>Temperature</term><term>Time Factors</term><term>Tumor Cells, Cultured</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the perspective of radioimmunotherapy (RIT) of micrometastases, we compared, in multicell spheroids (MS), the uptake and retention kinetics of 125I-F(ab)'2 F6 anti-carcinoembryonic antigen (CEA) monoclonal antibody (MAb), and the affinity enhancement system (AES) using an anti-CEA/anti-DTPA-indium bispecific antibody (BsMAb) and a 125I-labeled di-DTPA-In-tyrosine-lysine bivalent hapten. We used MS of colorectal tumor cell lines expressing CEA strongly (LS 174T), weakly (HT-29) or not at all (HRT-18). Uptake and retention kinetics of 125I-F(ab)'2 F6 and 125I-BsMAb used alone gave similar results. The highest uptake values, obtained with LS 174T MS, were slightly lower with AES than with 125I-F(ab)'2 F6. However, effective retention half-lives were longer for AES than for 125I-F(ab)'2 F6 or for 111In-labeled monovalent hapten after pre-incubation of spheroids with BsMAb. Autoradiography showed the same slow and heterogeneous distribution of 125I-F(ab)'2 F6 and 125I-BsMAb. These results indicate that the 2-step technique is more favorable for RIT: uptake values were approximately the same but uptake kinetics were more rapid, and retention half-life was longer than with the one-step technique.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8824563</PMID><DateCreated><Year>1996</Year><Month>11</Month><Day>22</Day></DateCreated><DateCompleted><Year>1996</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2007</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0020-7136</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>1996</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of cancer. Journal international du cancer</Title><ISOAbbreviation>Int. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.</ArticleTitle><Pagination><MedlinePgn>883-91</MedlinePgn></Pagination><Abstract><AbstractText>In the perspective of radioimmunotherapy (RIT) of micrometastases, we compared, in multicell spheroids (MS), the uptake and retention kinetics of 125I-F(ab)'2 F6 anti-carcinoembryonic antigen (CEA) monoclonal antibody (MAb), and the affinity enhancement system (AES) using an anti-CEA/anti-DTPA-indium bispecific antibody (BsMAb) and a 125I-labeled di-DTPA-In-tyrosine-lysine bivalent hapten. We used MS of colorectal tumor cell lines expressing CEA strongly (LS 174T), weakly (HT-29) or not at all (HRT-18). Uptake and retention kinetics of 125I-F(ab)'2 F6 and 125I-BsMAb used alone gave similar results. The highest uptake values, obtained with LS 174T MS, were slightly lower with AES than with 125I-F(ab)'2 F6. However, effective retention half-lives were longer for AES than for 125I-F(ab)'2 F6 or for 111In-labeled monovalent hapten after pre-incubation of spheroids with BsMAb. Autoradiography showed the same slow and heterogeneous distribution of 125I-F(ab)'2 F6 and 125I-BsMAb. These results indicate that the 2-step technique is more favorable for RIT: uptake values were approximately the same but uptake kinetics were more rapid, and retention half-life was longer than with the one-step technique.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devys</LastName><ForeName>A</ForeName><Initials>A</Initials><Affiliation>Unité 211 INSERM, Institut de Biologie, Nantes, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Thedrez</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gautherot</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Faivre-Chauvet</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Saï-Maurel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rouvier</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Auget</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Barbet</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chatal</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Comparative Study</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Int J Cancer</MedlineTA><NlmUniqueID>0042124</NlmUniqueID><ISSNLinking>0020-7136</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Immunoglobulin Fab Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Iodine Radioisotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Bispecific</DescriptorName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName><QualifierName MajorTopicYN="Y">immunology</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Colonic Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunoglobulin Fab Fragments</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Microscopy, Electron, Scanning</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioimmunotherapy</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Spheroids, Cellular</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>9</Month><Day>17</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8824563</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1097-0215(19960917)67:6<883::AID-IJC20>3.0.CO;2-1</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1097-0215(19960917)67:6<883::AID-IJC20>3.0.CO;2-1</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004483 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004483 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:8824563
|texte= Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:8824563" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |